Onc.AI is a digital health company developing AI-driven solutions to improve oncology decision-making, primarily by analyzing routine diagnostic imaging like CT scans to predict clinical outcomes in metastatic lung cancer.[1][2][4] It builds products such as Lung Clinical Management (LCM), under FDA review, and Serial CT Response Score (Serial CTRS), which received FDA Breakthrough Device Designation in January 2025, serving medical oncologists, pharmaceutical companies, and clinical trial teams.[1][4][5] These tools solve the problem of imprecise oncology treatment by extracting biomarkers for tumor burden, vascularity, body composition, and survival predictions, using a large real-world dataset of imaging, EMR, labs, and genomics data.[1][4] With $33 million raised, 20-50 employees, and backing from investors like Sandbox/Blue Venture Fund and Action Potential Venture Capital, Onc.AI shows strong growth, including validations in Pfizer and GSK trials presented at AACR 2025.[3][5]
Onc.AI was founded in 2020 by Akshay Nanduri (CEO) and Salmaan Ahmed, both with expertise in software for clinical oncology, genomics, proteomics, and radiomics.[3] Headquartered in San Carlos, California, with additional presence in the SF Bay Area and Waterloo, Ontario, the company emerged to address gaps in precision oncology by applying deep learning to real-world datasets.[1][2][3][4] Early traction came from building a market-leading oncology dataset and developing initial AI models for metastatic lung cancer outcomes, leading to FDA submissions, NCI SBIR support (1R44CA291456-01A1), and partnerships with pharma giants like Pfizer and GSK for clinical validations.[1][4][5]
Onc.AI rides the AI-precision oncology wave, where deep learning on multi-modal data (imaging, genomics, EMR) enables personalized treatment amid rising cancer immunotherapy adoption, like PD-1 therapies for NSCLC.[1][2][4] Timing aligns with FDA's push for AI tools—Breakthrough Designation and ONC's 2025 transparency rules for predictive decision support—accelerating adoption in clinical trials and care.[4][5][6] Market forces favor it: exploding oncology data volumes, pharma need for efficient trials, and clinician demand for prognostic insights beyond human detection.[1][5] It influences the ecosystem by setting benchmarks for imaging AI (e.g., outperforming RECIST), partnering with biopharma (GSK, Pfizer), and contributing to NCI-funded innovation, potentially standardizing AI biomarkers in oncology workflows.[4][5]
Onc.AI is poised for expansion with FDA clearances imminent for LCM and Serial CTRS, unlocking point-of-care adoption and broader pharma integrations beyond lung cancer.[4][5] Trends like AI regulatory acceleration, real-world evidence mandates, and multi-omics integration will propel its pipeline, while AACR validations boost credibility for Series A-scale funding or acquisitions.[3][5] Its influence may evolve from niche predictor to ecosystem platform, powering global oncology decisions and shaping precision medicine—turning Onc.AI from dataset pioneer to treatment clarity leader, fulfilling its mission to radicalize oncology outcomes.[1]
Onc.AI has raised $31.0M in total across 2 funding rounds.
Onc.AI's investors include Action Potential Venture Capital, Accomplice VC, Arthur Ventures, Brightspark Ventures, Emerald Technology Ventures, First Round Capital, Javelin Venture Partners, Lowercarbon Capital, Polaris Partners, Radical Ventures, Saltagen Ventures, Sandbox Industries.
Onc.AI has raised $31.0M across 2 funding rounds. Most recently, it raised $25.0M Series A in January 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2023 | $25.0M Series A | Action Potential Venture Capital | |
| Dec 1, 2020 | $6.0M Seed | Accomplice VC, Arthur Ventures, Brightspark Ventures, Emerald Technology Ventures, First Round Capital, Javelin Venture Partners, Lowercarbon Capital, Polaris Partners, Radical Ventures, Saltagen Ventures, Sandbox Industries, Uncork Capital, Avid Larizadeh, Edith Harbaugh, Matt Mazzeo, Ryan Carlson, Yan-David Erlich |
